Refined risk stratification in residual triple-negative breast cancer after neoadjuvant therapy using residual cancer burden class and lymphovascular invasion
Authors:
- Tae Hoon LeeTLTae Hoon Lee
- Hyunwoo LeeHLHyunwoo Lee
- Jeong Yun JangJJJeong Yun Jang
- Won ParkWPWon Park
- Won Kyung ChoWCWon Kyung Cho
- Eun Yoon ChoECEun Yoon Cho
- Jin Seok AhnJAJin Seok Ahn
- Yeon Hee ParkYeon Hee Park
- Seok Jin NamSNSeok Jin Nam
- Seok Won KimSKSeok Won Kim
- Jeong Eon LeeJLJeong Eon Lee
- Haeyoung KimHKHaeyoung Kim
Open Access
- 5 February 2026
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 215 (3) , 76
Abstract
Purpose This study aimed to identify prognostic factors and to stratify recurrence risk using a prognostic model incorporating the identified factors in patients with residual triple-negative breast cancer (TNBC) following neoadjuvant systemic therapy (NST). Methods A retrospective analysis was conducted using data from a prospectively collected single-institution database. Eligible patients had residual TNBC after NST and curative surgery between 2007 and 2020 and completed planned postoperative radiotherapy. Prognostic factors for disease-free survival (DFS) were identified using multivariable Cox proportional hazards regression. Risk groups were stratified according to the number of these factors. Results A total of 347 patients were included. With a median follow-up of 61.6 months, the 5-year DFS and overall survival rates were 62.5% and 73.9%, respectively. Lymphovascular invasion (LVI) positivity and residual cancer burden (RCB) class 3 were significant risk factors for worse DFS. The 5-year DFS rates were 82.9% (0 factor), 55.7% (1 factor), and 20.0% (2 factors) (p < 0.001). The new three-tiered stratification using LVI positivity and RCB class 3 demonstrated a higher concordance index compared to RCB class (bootstrap-estimated difference 0.038, 95% CI 0.006–0.070, p = 0.026). Adjuvant capecitabine was associated with improved 5-year DFS in patients with 1 risk factor (71.9% vs. 44.2%, p = 0.027), but not in those with 0 (83.1% vs. 81.7%, p = 0.548) or 2 factors (29.2% vs. 14.6%, p = 0.066). Conclusion Patients with residual TNBC can be stratified into risk groups based on LVI and RCB class. The effect of adjuvant treatment varied across these groups. This model may support more tailored adjuvant treatment decisions after NST.Keywords
Funding Information
- National Research Foundation of Korea (RS-2023-00252283)
- Samsung Medical Center, Sungkyunkwan University (SMO1240501)
- Sungkyunkwan University
This publication has 38 references indexed in Scilit:
- Efficacy of adjuvant capecitabine in triple-negative breast cancer with residual disease after neoadjuvant therapy: a real-world studyThe Breast, 2025
- Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522Annals of Oncology, 2024
- Treatment of residual disease following neoadjuvant therapy in breast cancerJournal of Surgical Oncology, 2023
- The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibitionAnnals of Oncology, 2021
- Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast CancerJAMA Oncology, 2021
- Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapyBreast Cancer Research and Treatment, 2019
- Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinomaBreast Cancer Research and Treatment, 2018
- The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant ChemotherapyJAMA Oncology, 2016
- Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapyBreast Cancer Research and Treatment, 2016
- The prognostic significance of lymphovascular invasion in invasive breast carcinomaCancer, 2011